RT Journal Article
SR Electronic
T1 Altered dynamic functional connectivity in antagonistic state in first-episode, drug-naive patients with major depressive disorder
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.07.02.24309338
DO 10.1101/2024.07.02.24309338
A1 Wang, Min
A1 Chen, Tao
A1 He, Zhongyi
A1 Chan, Lawrence Wing-Chi
A1 Guo, Qinger
A1 Cai, Shuyang
A1 Duan, Jingfeng
A1 Zhang, Danbin
A1 Wang, Xunda
A1 Fang, Yu
A1 Yang, Hong
YR 2024
UL http://medrxiv.org/content/early/2024/07/03/2024.07.02.24309338.abstract
AB Major depressive disorder (MDD) is characterized by disrupted functional network connectivity (FNC), with unclear underlying dynamics. We investigated both static FNC (sFNC) and dynamic FNC (dFNC) on resting-state fMRI data from drug-naive first-episode MDD patients and healthy controls (HC). MDD patients exhibited lower sFNC within and between sensory and motor networks than HC. Four dFNC states were identified, including a globally-weakly-connected state, a cognitive-control-dominated state, a globally-positively-connected state, and an antagonistic state. The antagonistic state was marked by strong positive connections within the sensorimotor domain and their anti-correlations with the executive-motor control domain. Notably, MDD patients exhibited significantly longer time dwelling in the globally-weakly-connected state, at the cost of significantly shorter time dwelling in the antagonistic state. Further, only the mean dwell time of this antagonistic state was significantly anticorrelated to disease severity measures. Our study highlights the altered dynamics of the antagonistic state as a fundamental aspect of disrupted FNC in early MDD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Natural Science Foundation of China (Grant No. 32301159), the Science Technology Department of Zhejiang Province (Grant No. 2022C03029), the Basic Public Welfare Research Program of Zhejiang Province (Grant No. LGF20H090013), the Key Research and Development Program, Ministry of Science and Technology of People's Republic of China (Grant No. 2019YFC0121003).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Clinical Research Ethics Committee, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available from the corresponding authors, Min Wang and Hong Yang, upon reasonable request. The raw data are not publicly available and only available on reasonable request due to information that could compromise the privacy of the research participants.